Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway

Mercedes Rincon, Hervé Enslen, Joël Raingeaud, Michael Recht, Tyler Zapton, Michael S S Su, Laurie A. Penix, Roger J. Davis, Richard A. Fiavell

Research output: Contribution to journalArticle

349 Citations (Scopus)

Abstract

Signal transduction via MAP kinase pathways plays a key role in a variety of cellular responses, including growth factor-induced proliferation, differentiation and cell death. In mammalian cells, p38 MAP kinase can be activated by multiple stimuli, such as pro-inflammatory cytokines and environmental stress. Although p38 MAP kinase is implicated in the control of inflammatory responses, the molecular mechanisms remain unclear. Upon activation, CD4+ T cells differentiate into Th2 cells, which potentiate the humoral immune response or pro-inflammatory Th1 cells. Here, we show that pyridinyl imidazole compounds (specific inhibitors of p38 MAP kinase) block the production of interferon-γ (IFNγ) by Th1 cells without affecting IL-4 production by Th2 cells. These drugs also inhibit transcription driven by the IFNγ promoter. In transgenic mice, inhibition of the p38 MAP kinase pathway by the expression of dominant-negative p38 MAP kinase results in selective impairment of Th1 responses, In contrast, activation of the p38 MAP kinase pathway by the expression of constitutively-activated MAP kinase kinase 6 in transgenic mice caused increased production of IFNγ during the differentiation and activation of Th1 cells. Together, these data demonstrate that the p38 MAP kinase is relevant for Th1 cells, not Th2 cells, and that inhibition of p38 MAP kinase represents a possible site of therapeutic intervention in diseases where a predominant Th1 immune response leads to a pathological outcome. Moreover, our study provides an additional mechanism by which the p38 MAP kinase pathway controls inflammatory responses.

Original languageEnglish (US)
Pages (from-to)2817-2829
Number of pages13
JournalEMBO Journal
Volume17
Issue number10
DOIs
StatePublished - May 15 1998
Externally publishedYes

Fingerprint

T-cells
MAP Kinase Signaling System
p38 Mitogen-Activated Protein Kinases
Interferons
T-Lymphocytes
Th1 Cells
Th2 Cells
Chemical activation
Transgenic Mice
MAP Kinase Kinase 6
Signal transduction
Cell death
Transcription
Humoral Immunity
Interleukin-4
Signal Transduction
Intercellular Signaling Peptides and Proteins
Cell Death
Phosphotransferases
Cells

Keywords

  • IFNγ
  • p38 MAP kinase
  • T-cell differentiation
  • Th1 cells
  • Transgenic mice

ASJC Scopus subject areas

  • Genetics
  • Cell Biology

Cite this

Rincon, M., Enslen, H., Raingeaud, J., Recht, M., Zapton, T., Su, M. S. S., ... Fiavell, R. A. (1998). Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO Journal, 17(10), 2817-2829. https://doi.org/10.1093/emboj/17.10.2817

Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. / Rincon, Mercedes; Enslen, Hervé; Raingeaud, Joël; Recht, Michael; Zapton, Tyler; Su, Michael S S; Penix, Laurie A.; Davis, Roger J.; Fiavell, Richard A.

In: EMBO Journal, Vol. 17, No. 10, 15.05.1998, p. 2817-2829.

Research output: Contribution to journalArticle

Rincon, M, Enslen, H, Raingeaud, J, Recht, M, Zapton, T, Su, MSS, Penix, LA, Davis, RJ & Fiavell, RA 1998, 'Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway', EMBO Journal, vol. 17, no. 10, pp. 2817-2829. https://doi.org/10.1093/emboj/17.10.2817
Rincon, Mercedes ; Enslen, Hervé ; Raingeaud, Joël ; Recht, Michael ; Zapton, Tyler ; Su, Michael S S ; Penix, Laurie A. ; Davis, Roger J. ; Fiavell, Richard A. / Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. In: EMBO Journal. 1998 ; Vol. 17, No. 10. pp. 2817-2829.
@article{ab8507fb7a804acba8e90cffbe2de0c9,
title = "Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway",
abstract = "Signal transduction via MAP kinase pathways plays a key role in a variety of cellular responses, including growth factor-induced proliferation, differentiation and cell death. In mammalian cells, p38 MAP kinase can be activated by multiple stimuli, such as pro-inflammatory cytokines and environmental stress. Although p38 MAP kinase is implicated in the control of inflammatory responses, the molecular mechanisms remain unclear. Upon activation, CD4+ T cells differentiate into Th2 cells, which potentiate the humoral immune response or pro-inflammatory Th1 cells. Here, we show that pyridinyl imidazole compounds (specific inhibitors of p38 MAP kinase) block the production of interferon-γ (IFNγ) by Th1 cells without affecting IL-4 production by Th2 cells. These drugs also inhibit transcription driven by the IFNγ promoter. In transgenic mice, inhibition of the p38 MAP kinase pathway by the expression of dominant-negative p38 MAP kinase results in selective impairment of Th1 responses, In contrast, activation of the p38 MAP kinase pathway by the expression of constitutively-activated MAP kinase kinase 6 in transgenic mice caused increased production of IFNγ during the differentiation and activation of Th1 cells. Together, these data demonstrate that the p38 MAP kinase is relevant for Th1 cells, not Th2 cells, and that inhibition of p38 MAP kinase represents a possible site of therapeutic intervention in diseases where a predominant Th1 immune response leads to a pathological outcome. Moreover, our study provides an additional mechanism by which the p38 MAP kinase pathway controls inflammatory responses.",
keywords = "IFNγ, p38 MAP kinase, T-cell differentiation, Th1 cells, Transgenic mice",
author = "Mercedes Rincon and Herv{\'e} Enslen and Jo{\"e}l Raingeaud and Michael Recht and Tyler Zapton and Su, {Michael S S} and Penix, {Laurie A.} and Davis, {Roger J.} and Fiavell, {Richard A.}",
year = "1998",
month = "5",
day = "15",
doi = "10.1093/emboj/17.10.2817",
language = "English (US)",
volume = "17",
pages = "2817--2829",
journal = "EMBO Journal",
issn = "0261-4189",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway

AU - Rincon, Mercedes

AU - Enslen, Hervé

AU - Raingeaud, Joël

AU - Recht, Michael

AU - Zapton, Tyler

AU - Su, Michael S S

AU - Penix, Laurie A.

AU - Davis, Roger J.

AU - Fiavell, Richard A.

PY - 1998/5/15

Y1 - 1998/5/15

N2 - Signal transduction via MAP kinase pathways plays a key role in a variety of cellular responses, including growth factor-induced proliferation, differentiation and cell death. In mammalian cells, p38 MAP kinase can be activated by multiple stimuli, such as pro-inflammatory cytokines and environmental stress. Although p38 MAP kinase is implicated in the control of inflammatory responses, the molecular mechanisms remain unclear. Upon activation, CD4+ T cells differentiate into Th2 cells, which potentiate the humoral immune response or pro-inflammatory Th1 cells. Here, we show that pyridinyl imidazole compounds (specific inhibitors of p38 MAP kinase) block the production of interferon-γ (IFNγ) by Th1 cells without affecting IL-4 production by Th2 cells. These drugs also inhibit transcription driven by the IFNγ promoter. In transgenic mice, inhibition of the p38 MAP kinase pathway by the expression of dominant-negative p38 MAP kinase results in selective impairment of Th1 responses, In contrast, activation of the p38 MAP kinase pathway by the expression of constitutively-activated MAP kinase kinase 6 in transgenic mice caused increased production of IFNγ during the differentiation and activation of Th1 cells. Together, these data demonstrate that the p38 MAP kinase is relevant for Th1 cells, not Th2 cells, and that inhibition of p38 MAP kinase represents a possible site of therapeutic intervention in diseases where a predominant Th1 immune response leads to a pathological outcome. Moreover, our study provides an additional mechanism by which the p38 MAP kinase pathway controls inflammatory responses.

AB - Signal transduction via MAP kinase pathways plays a key role in a variety of cellular responses, including growth factor-induced proliferation, differentiation and cell death. In mammalian cells, p38 MAP kinase can be activated by multiple stimuli, such as pro-inflammatory cytokines and environmental stress. Although p38 MAP kinase is implicated in the control of inflammatory responses, the molecular mechanisms remain unclear. Upon activation, CD4+ T cells differentiate into Th2 cells, which potentiate the humoral immune response or pro-inflammatory Th1 cells. Here, we show that pyridinyl imidazole compounds (specific inhibitors of p38 MAP kinase) block the production of interferon-γ (IFNγ) by Th1 cells without affecting IL-4 production by Th2 cells. These drugs also inhibit transcription driven by the IFNγ promoter. In transgenic mice, inhibition of the p38 MAP kinase pathway by the expression of dominant-negative p38 MAP kinase results in selective impairment of Th1 responses, In contrast, activation of the p38 MAP kinase pathway by the expression of constitutively-activated MAP kinase kinase 6 in transgenic mice caused increased production of IFNγ during the differentiation and activation of Th1 cells. Together, these data demonstrate that the p38 MAP kinase is relevant for Th1 cells, not Th2 cells, and that inhibition of p38 MAP kinase represents a possible site of therapeutic intervention in diseases where a predominant Th1 immune response leads to a pathological outcome. Moreover, our study provides an additional mechanism by which the p38 MAP kinase pathway controls inflammatory responses.

KW - IFNγ

KW - p38 MAP kinase

KW - T-cell differentiation

KW - Th1 cells

KW - Transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=0032525233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032525233&partnerID=8YFLogxK

U2 - 10.1093/emboj/17.10.2817

DO - 10.1093/emboj/17.10.2817

M3 - Article

C2 - 9582275

AN - SCOPUS:0032525233

VL - 17

SP - 2817

EP - 2829

JO - EMBO Journal

JF - EMBO Journal

SN - 0261-4189

IS - 10

ER -